Literature DB >> 8954948

Interleukin-4 activates two distinct pathways of phosphatidylinositol-3 kinase in the same cells.

K Izuhara1, N Harada.   

Abstract

We have recently demonstrated that c-fes protooncogene product (FES), or a FES-related protein, associates with the interleukin-4 receptor alpha chain (IL-4R alpha) and phosphatidylinositol-3 (PI3) kinase in mouse T cell lines; however, others have demonstrated that PI3 kinase associates with IL-4R alpha through tyrosine phosphorylated insulin receptor substrate (IRS)-2 in other cell types. In order to examine whether IL-4 activates these two distinct PI3 kinase pathways in the same cells, we analyzed association of PI3 kinase with IRS-2, and tyrosine phosphorylation of IRS-2, in a mouse pro-B cell line, Ba/F3, and a mouse mast cell line, MC9. In both cell lines, IL-4 induced tyrosine phosphorylation of IRS-2, association of PI3 kinase with IRS-2, and FES or a FES-related protein. These results indicate that IL-4 activates two distinct PI3 kinase pathways in the same cells. We further identified the critical region in the cytoplasmic domain of IL-4R alpha required for tyrosine phosphorylation of IRS-2.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8954948     DOI: 10.1006/bbrc.1996.1854

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  2 in total

1.  A differential requirement for phosphoinositide 3-kinase reveals two pathways for inducible upregulation of major histocompatibility complex class II molecules and CD86 expression by murine B lymphocytes.

Authors:  Stuart Marshall-Clarke; Lynn Tasker; Mark P Heaton; R Michael E Parkhouse
Journal:  Immunology       Date:  2003-05       Impact factor: 7.397

2.  Interleukin4Rα (IL4Rα) and IL13Rα1 Are Associated with the Progress of Renal Cell Carcinoma through Janus Kinase 2 (JAK2)/Forkhead Box O3 (FOXO3) Pathways.

Authors:  Mi-Ae Kang; Jongsung Lee; Sang Hoon Ha; Chang Min Lee; Kyoung Min Kim; Kyu Yun Jang; See-Hyoung Park
Journal:  Cancers (Basel)       Date:  2019-09-18       Impact factor: 6.639

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.